Sector News

AstraZeneca snaps up Alexion for $39B in a leap toward CEO’s $40B revenue goal

December 13, 2020
Life sciences

Just when Gilead Sciences’ $21 billion acquisition of Immunomedics looked to be 2020’s biggest biopharma deal, AstraZeneca came up with an even larger one—and it involves one of the industry’s top takeover targets.

AstraZeneca is splashing out $39 billion to buy Alexion in a cash-and-stock deal, the British pharma revealed Saturday. The deal is driven by AstraZeneca’s desire to build a stronger presence in immunology—and to give its top line an immediate boost.

The deal values Alexion at $175 per share, a 45% premium to the Boston biotech’s closing price on Friday. As part of the cost will be paid in AstraZeneca shares, Alexion investors will own about 15% of the combined enterprise when the deal closes, likely in the third quarter of 2021.

“Alexion has established itself as a leader in complement biology, bringing life-changing benefits to patients with rare diseases,” AstraZeneca CEO Pascal Soriot said in a statement. “This acquisition allows us to enhance our presence in immunology.”

It also makes Soriot’s target of $40 billion in sales by 2023 more attainable. Last year, the biotech brought in sales of $5 billion, up 21% year over year, led by blockbuster rare disease med Soliris. And Alexion management has set a 2025 revenue target of about $9 billion to $10 billion. In comparison, AZ’s global sales hit $23.6 billion in 2019, year-over-year boost of 12%.

AZ is grabbing a prize that doesn’t obviously fit with its own portfolio, but one that’s been a frequent guest on industry watchers’ lists of top takeover targets, given its established portfolio and expertise in rare diseases. It’s also the No.1 pick on Fierce Biotech’s most recent biopharma acquisition target roster, compiled with Jefferies analyst Jared Holz.

Holz previously noted that Alexion has been one of the cheapest stocks among mid- to large-cap biotechs based on its price-earnings ratio.

In an August investor’s note, SVB Leerink analyst Geoffrey Porges labeled Alexion as a “rare M&A-ready large biopharma.” At that time, he listed Sanofi, Pfizer, Biogen and Novartis as possible suitors based on their existing interest in rare disease, ranking AZ and several other Big Pharmas at the bottom because of their low exposure in the field.

AstraZeneca boasts a strong position in cancer, led by lung cancer drug Tagrisso, PARP inhibitor Lynparza and PD-L1 agent Imfinzi. It also sells products in cardiovascular, renal and metabolic diseases. The company recently pivoted to develop a COVID-19 vaccine, AZD1222, in a partnership with Oxford University, and it’s also working on an anti-coronavirus antibody cocktail.

In immunology, its approved products are crossovers from the respiratory field, though it just regained rights to an inflammatory bowel disease candidate, brazikumab. Allergan returned the anti-IL-23 antibody to win antitrust clearance for its $63 billion merger with AbbVie.

Now, AZ’s buying Alexion for its knowledge in immune-mediated diseases. Alexion’s portfolio includes Soliris and Ultomiris, which target C5, a key piece of the immune system. In addition, Alexion’s pipeline includes 11 molecules, targeting Factor D, FcRn and others.

The $39 billion price tag roughly falls in Porges’ previous estimate of $34 billion at a “reasonable” premium of around 50%. But now, he argued that the price is too low.

“[I]n today’s inflated market, we believe investors could demand more from AstraZeneca, or another acquirer,” he wrote in a Saturday note. “This is such a scarce and high-quality asset that in this instance, the final transaction price may need to reach $200 to satisfy Alexion’s shareholders, or to be based more in cash, rather than predominantly stock.”

Under the terms of the agreement, $60 will go to Alexion shareholders in cash, with the rest paid in AstraZeneca shares.

Alexion investors have had concerns over the company’s overreliance on the Soliris-Ultomiris franchise. But AZ highlighted Alexion’s success in transitioning more than 70% of paroxysmal nocturnal hemoglobinuria patients from Soliris to Ultomiris in less than two years as proof of Alexion’s skillful commercial execution.

The Boston biotech has made several M&A moves itself, but not exactly to investors’ satisfaction. In July, Alexion ditched its lead asset from a $930 million Achillion buyout after disappointing phase 2 data. In May, it paid $1.4 billion to Portola Pharmaceuticals for an underperforming anticoagulant reversal agent called Andexxa, though execs believe the drug will deliver over the long run.

“Alexion’s franchise is far more valuable in the hands of a large diversified company than it is independently,” Porges said, adding that rare diseases are one of the most attractive business segments in biopharma. The buyout “immediately elevates AstraZeneca into the top tier of the category,” he said.

by Angus Liu

Source: fiercepharma.com

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

January 23, 2021

Thermo Fisher Scientific acquires Novasep’s Henogen for $874.5m

Life sciences

Thermo Fisher Scientific has acquired Novasep’s viral vector manufacturing business in Belgium, Henogen, for about €725m ($874.5m) in cash. Henogen offers biotechnology firms, as well as biopharma customers contract manufacturing services for vaccines and therapies.

January 23, 2021

Lilly and Merus partner to develop T-Cell re-directing antibody therapies

Life sciences

Research and development group of Eli Lilly and Company, Loxo Oncology at Lilly, and clinical-stage oncology company Merus have announced a research collaboration and exclusive license agreement to develop T-Cell re-directing bispecific antibodies.

January 23, 2021

Adagene plans $125M IPO to go after cancer niches targeted by BMS and Pfizer

Life sciences

Chinese cancer biotech Adagene has filed to raise up to $125 million in a Nasdaq IPO. The listing will give Adagene the means to run early-phase clinical trials of antibodies against CD137 and CTLA-4.

Send this to a friend